{"contentid": 488404, "importid": NaN, "name": "Evotec ups investment in biologic manufacturing facility in Toulouse", "introduction": "Shares of German biotech Evotec were up 2.3% at 34.39 euros by late afternoon today after it said it has initiated the construction of its J.POD 2 EU biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France.", "content": "<p>Shares of German biotech Evotec (EVT: Xetra) were up 2.3% at 34.39 euros by late afternoon today after it said it has initiated the construction of its J.POD 2 EU biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France.</p>\n<p>J.POD 2 EU, Evotec's second innovative cGMP biomanufacturing facility, will employ Just - Evotec Biologics' cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms.<br /> <br /> J.POD 2 EU will be Evotec's first commercial biomanufacturing facility in Europe and is anticipated to deliver much needed capacity, flexibility and quality for biotherapeutic development and manufacturing. The construction of Evotec's first J.POD 1 US in Redmond, Washington, USA, is proceeding on schedule and will be fully operational in second-half 2021.</p>\n<p>The build-up of J.POD 2 EU will be supported with up to 50 milli euros ($60.1 million) from the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture as well as Toulouse M&eacute;tropole. The total investment that Evotec plans to undertake is currently estimated at around 150 million euros.</p>\n<h2><strong>Building capacity required for the fight against COVID-19</strong></h2>\n<p>With its wholly owned subsidiary, Just - Evotec Biologics, Evotec is ideally positioned to build the capacity required for the fight against COVID-19 and future pandemic threats delivering rapid, high quality outcomes. Evotec is supporting multiple projects against COVID-19, including partnerships with the Bill &amp; Melinda Gates Foundation and the United States Department of Defense.<br /> <br /> In addition to J.POD technology, Evotec is building unparalleled data-driven scientific capabilities to meet future viral threats, which include fast discovery, optimisation and development of novel therapeutic agents.<br /> <br /> Evotec's Toulouse site, the Campus Curie, was recently expanded through the acquisition of \"Biopark by Sanofi.\" Evotec has been operating in France since 2015. Construction of the J.POD 2 EU facility is expected to begin in the second half of 2021, and is expected to be fully operational in 2023.</p>", "date": "2021-04-20 14:48:00", "meta_title": "Evotec ups investment in biologic manufacturing facility in Toulouse", "meta_keywords": "Evotec, Manufacturing, Facility, Investment, Toulouse, Capacity, Pandemics, COVID-19", "meta_description": "Evotec ups investment in biologic manufacturing facility in Toulouse", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-20 14:47:17", "updated": "2021-04-20 14:53:31", "access": NaN, "url": "https://www.thepharmaletter.com/article/evotec-ups-investment-in-biologic-manufacturing-facility-in-toulouse", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "evotec-large.png", "image2id": "evotec-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": NaN, "topic_tag": "Coronavirus, Focus On, Production", "geography_tag": "France, Germany", "company_tag": "Evotec", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": "Campus Curie", "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-20 14:48:00"}